LIPELLA PHARMACEUTICALS INC (LIPO) Stock Price, Forecast & Analysis
USA - NASDAQ:LIPO - US53630L2097 - Common Stock
LIPO Key Statistics, Chart & Performance
The current stock price of LIPO is 2.36 USD. In the past month the price decreased by -23.38%. In the past year, price decreased by -48.25%.
LIPO Latest News, Press Relases and Analysis
LIPO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About LIPO
Company Profile
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.
Company Info
LIPELLA PHARMACEUTICALS INC
400 N Lexington St Ste LL103
Pittsburgh PENNSYLVANIA US
Employees: 5
Phone: 14129010315
LIPELLA PHARMACEUTICALS INC / LIPO FAQ
What does LIPO do?
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.
What is the current price of LIPO stock?
The current stock price of LIPO is 2.36 USD. The price decreased by -12.75% in the last trading session.
Does LIPO stock pay dividends?
LIPO does not pay a dividend.
What is the ChartMill technical and fundamental rating of LIPO stock?
LIPO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of LIPELLA PHARMACEUTICALS INC (LIPO)?
LIPELLA PHARMACEUTICALS INC (LIPO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.1).
What is the outstanding short interest for LIPELLA PHARMACEUTICALS INC?
The outstanding short interest for LIPELLA PHARMACEUTICALS INC (LIPO) is 0.06% of its float.
LIPO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LIPO. When comparing the yearly performance of all stocks, LIPO is a bad performer in the overall market: 90.5% of all stocks are doing better.
LIPO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LIPO. While LIPO has a great health rating, there are worries on its profitability.
LIPO Financial Highlights
Over the last trailing twelve months LIPO reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS decreased by -56.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.66% | ||
| ROE | -125.78% | ||
| Debt/Equity | 0 |
LIPO Forecast & Estimates
7 analysts have analysed LIPO and the average price target is 10.2 USD. This implies a price increase of 332.2% is expected in the next year compared to the current price of 2.36.
For the next year, analysts expect an EPS growth of 33.76% and a revenue growth -100% for LIPO